ArticleBrain and behavior2026
Neutrophil-Monocyte-to-Lymphocyte Ratio as a Valid Prognostic Tool for Acute Ischemic Stroke With Performance Comparable to Neutrophil-to-Lymphocyte Ratio.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInflammation is a key mediator for brain injury in acute ischemic stroke (AIS) and the neutrophil-monocyte-to-lymphocyte ratio (NMLR) is a novel composite index for inflammatory. So far, prior studies have not evaluated the prognostic value of NMLR for 3-month functional outcomes in patients with AIS, nor systematically compared its performance with established markers, such as neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and individual cellular components. This prospective cohort study aims to address these research gaps.
methodsA total of 815 consecutive patients with AIS hospitalized between December 2023 and May 2024 were enrolled. Baseline clinical data and blood samples were collected within 24 h of admission. The primary outcome was poor 90-day functional outcome (modified Rankin Scale score > 2). Multivariable logistic regression determined adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the outcome association of NMLR. Receiver operating characteristic (ROC) curve analysis compared the predictive performance (area under the curve [AUC]) of NMLR with NLR, MLR, and individual cellular components.
resultsOf the 815 patients, 224 (27.5%) had poor functional outcomes. After adjusting for confounders, higher NMLR was independently associated with increased risk of poor outcomes (aOR = 1.370 per unit increase, 95% CI: 1.214-1.546; p < 0.001). NMLR's predictive performance (AUC = 0.708, 95% CI: 0.668-0.749) was statistically equivalent to NLR (AUC = 0.709, p = 0.594), but significantly superior to MLR and individual cellular components (all p < 0.05).
conclusionsThis is the first prospective study to assess the predictive value of the NMLR for 3-month functional outcomes in patients with AIS and systematically compare NMLR with NLR. NMLR can predict poor 90-day outcomes in patients with AIS independently. NMLR is a valid prognostic tool for AIS with performance comparable to NLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.